Literature DB >> 20856628

Are There Any Differences in the Clinical and Economic Outcomes Between US Cancer Patients Receiving Appropriate or Inappropriate Venous Thromboembolism Prophylaxis?

Alpesh N Amin1, Jay Lin, Guiping Yang, Stephen Stemkowski.   

Abstract

Prophylaxis is often underused and inappropriately prescribed. This study compares the efficacy and cost of appropriate and partial prophylaxis in cancer patients at risk for VTE.

Entities:  

Year:  2009        PMID： 20856628      PMCID： PMC2795419          DOI： 10.1200/JOP.0942002

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  19 in total

1.  Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group.

Authors: 
Journal:  Br J Surg       Date:  1997-08       Impact factor: 6.939

2.  Venous thromboembolic disease. Clinical practice guidelines in oncology.

Authors:  Lawrence D Wagman; Melissa F Baird; Charles L Bennett; Paula L Bockenstedt; Spero R Cataland; John Fanikos; Patrick F Fogarty; Samuel Z Goldhaber; Tejpal S Grover; William Haire; Hani Hassoun; Mohammad Jahanzeb; Lawrence L Leung; Michael L Linenberger; Michael M Millenson; Thomas L Ortel; Riad Salem; Judy L Smith; Michael B Streiff
Journal:  J Natl Compr Canc Netw       Date:  2006-10       Impact factor: 11.908

3.  Incidence of venous thromboembolism in patients hospitalized with cancer.

Authors:  Paul D Stein; Afzal Beemath; Frederick A Meyers; Elias Skaf; Julia Sanchez; Ronald E Olson
Journal:  Am J Med       Date:  2006-01       Impact factor: 4.965

Review 4.  A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals.

Authors:  Rebecca Tooher; Philippa Middleton; Clarabelle Pham; Robert Fitridge; Siohban Rowe; Wendy Babidge; Guy Maddern
Journal:  Ann Surg       Date:  2005-03       Impact factor: 12.969

5.  Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.

Authors:  David Bergqvist; Giancarlo Agnelli; Alexander T Cohen; Amiram Eldor; Paul E Nilsson; Anne Le Moigne-Amrani; Flavia Dietrich-Neto
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

6.  Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.

Authors:  J A Heit; D N Mohr; M D Silverstein; T M Petterson; W M O'Fallon; L J Melton
Journal:  Arch Intern Med       Date:  2000-03-27

7.  Thromboprophylaxis in medically ill patients at risk for venous thromboembolism.

Authors:  Edward Burleigh; Cheng Wang; David Foster; Sivana Heller; Dennis Dunn; Kaveh Safavi; Brian Griffin; Jeff Smith
Journal:  Am J Health Syst Pharm       Date:  2006-10-15       Impact factor: 2.637

8.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.

Authors:  M M Samama; A T Cohen; J Y Darmon; L Desjardins; A Eldor; C Janbon; A Leizorovicz; H Nguyen; C G Olsson; A G Turpie; N Weisslinger
Journal:  N Engl J Med       Date:  1999-09-09       Impact factor: 91.245

9.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

10.  Venous thrombosis in cancer patients: insights from the FRONTLINE survey.

Authors:  Ajay K Kakkar; Mark Levine; H M Pinedo; Robert Wolff; John Wong
Journal:  Oncologist       Date:  2003
View more
  4 in total

1.  Preventing venous thromboembolism in cancer patients: can we do better?

Authors:  Gary H Lyman
Journal:  J Oncol Pract       Date:  2009-07       Impact factor: 3.840

2.  Direct Medical Costs Attributable to Cancer-Associated Venous Thromboembolism: A Population-Based Longitudinal Study.

Authors:  Kevin P Cohoon; Jeanine E Ransom; Cynthia L Leibson; Aneel A Ashrani; Tanya M Petterson; Kirsten Hall Long; Kent R Bailey; John A Heit
Journal:  Am J Med       Date:  2016-03-21       Impact factor: 4.965

3.  Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States.

Authors:  Alok A Khorana; Mehul R Dalal; Jay Lin; Gregory C Connolly
Journal:  Clinicoecon Outcomes Res       Date:  2013-02-13

4.  Burden of asthma with elevated blood eosinophil levels.

Authors:  Julian Casciano; Jerry A Krishnan; Mary Buatti Small; Philip O Buck; Gokul Gopalan; Chenghui Li; Robert Kemp; Zenobia Dotiwala
Journal:  BMC Pulm Med       Date:  2016-07-13       Impact factor: 3.317
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.